Latent antithrombin and its detection, formation and turnover in the circulation

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 12, 2004, Pages 2170-2177

  Mushunje, A ^c   Evans, G ^a   Brennan, S O ^b   Carrell, R W ^c   Zhou, A ^c  

^a KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antithrombin; Half life; Latent; Plasma; Serpins; Urea PAGE

Indexed keywords

ANTITHROMBIN;

ANTITHROMBIN DEFICIENCY; ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; GENETIC VARIABILITY; HUMAN; IN VIVO STUDY; INCUBATION TIME; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; QUANTITATIVE ANALYSIS; RABBIT; SEPSIS;

ANIMALS; ANTITHROMBINS; BLOOD CIRCULATION; CATTLE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FACTOR XA; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; RABBITS; SERPINS; TEMPERATURE; TIME FACTORS; UREA;

EID: 13244269951     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.01047.x     Document Type: Article

References (34)

1. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285: 1926-8.
2. Larsson H, Sjoblom T, Dixelius J, Ostman A, Ylinenjarvi K, Bjork I, Claesson-Welsh L. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res 2000; 60: 6723-9.
3. Zhang W, Chuang YJ, Swanson R, Li J, Seo K, Leung L, Lau LF, Olson ST. Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004; 103: 1185-91.
4. Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Meth Enzymol 1993; 222: 525-59.
5. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923-6.
6. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-3.
7. Carrell RW, Evans DL, Stein PE. Mobile reactive centre of serpins and the control of thrombosis. Nature 1991; 353: 576-8.
8. Wardell MR, Abrahams J-P, Bruce D, Skinner R, Leslie AGW. Crystallization and preliminary X-ray diffraction analysis of two conformations of intact human antithrombin. J Mol Biol 1993; 234 1253-8.
9. Carrell RW, Stein PE, Fermi G, Wardell MR. Biological implications of a 3 A structure of dimeric antithrombin. Structure 1994; 2: 257-70.
10. Skinner R, Abrahams JP, Whisstock JC, Lesk AM, Carrell RW, Wardell MR. The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol 1997; 266: 601-9.
11. 1-antitrypsin. J Mol Biol 1992; 224: 241-52.
12. Lane DA, Olds RJ, Conard J, Boisclair M, Bock SC, Hultin M, Abildgaard U, Ireland H, Thompson E, Sas G, Horellou MH, Tamponi G, Thein SL. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest 1992; 90: 2422-33.
13. Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN, Millar DS, Jochmans K, Perry DJ, Okajima K, Thein SL, Emmerich J. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997; 77: 197-211.
14. Bruce D, Perry DJ, Borg JY, Carrell RW, Wardell MR. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn → Asp). J Clin Invest 1994; 94 2265-74.
15. Emmerich J, Chadeuf G, Coetzee MJ, Alhenc-Gelas M, Fiessinger JN, Aiach M. A phenylalanine 402 to leucine mutation is responsible for a stable inactive conformation of antithrombin. Thromb Res 1994; 76: 307-15.
16. Beauchamp NJ, Pike RN, Daly M, Butler L, Makris M, Dafforn TR, Zhou A, Fitton HL, Preston FE, Peake IR, Carrell RW. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood 1998; 92: 2696-706.
17. Zhou A, Huntington JA, Carrell RW. Formation of the antithrombin heterodimer and the onset of thrombosis. Blood 1999; 94: 3388-96.
18. McKay EJ. A simple two-step procedure for the isolation of antithrombin III from biological fluids. Thromb Res 1981; 21: 375-82.
19. Carrell RW, Huntington JA, Mushunje A, Zhou A. The conformational basis of thrombosis. Thromb Haemost 2001; 86: 14-22.
20. Zhou A, Stein PE, Huntington JA, Carrell RW. Serpin polymerization is prevented by a hydrogen bond network that is centered on his-334 and stabilized by glycerol. J Biol Chem 2003; 278: 15116-22.
21. Nordenman B, Nystrom C, Bjork I. The size and shape of human and bovine antithrombin III. Eur J Biochem 1977; 78: 195-203.
22. Abildaard U, Lie M, Odegard OR. A simple amidolytic method for the determination of functional active antithrombin III. Scand J Clin Lab Invest 1976; 36: 109-12.
23. Creighton TE. Protein Structure, a Practical Approach. The Practical Approach Series. Rickwood D, Hames BD, eds. Oxford: IRL Press at Oxford University Press, 1989.
24. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
25. Murano G, Williams L, Miller-Andersson M, Aronson DL, King C. Some properties of antithrombin-III and its concentration in human plasma. Thromb Res 1980; 18: 259-62.
26. Marchalonis JJ. An enzymic method for the trace iodination of immunoglobulins and other proteins. Biochem J 1969; 113: 299-305.
27. Carlson TH, Atencio AC, Simon TL. In vivo behavior of radioiodinated rabbit antithrombin III. Demonstration of a noncirculating vascular compartment. J Clin Invest 1984; 74: 191-9.
28. Wells MJ, Blajchman MA. In vivo clearance of ternary complexes of vitronectin-thrombin-antithrombin is mediated by hepatic heparan sulfate proteoglycans. J Biol Chem 1998; 273: 23440-7.
29. Mast AE, Enghild JJ, Pizzo SV, Salvesen G. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 1991; 30: 1723-30.
30. Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding affinity. Proc Natl Acad Sci USA 1984; 81: 289-93.
31. Erdjument H, Lane DA, Ireland H, Di Marzo V, Panico M, Morris HR, Tripodi A, Mannucci PM. Antithrombin Milano, single amino acid substitution at the reactive site, Arg393 to Cys. Thromb Haemost 1988; 60: 471-5.
32. Mushunje A, Zhou A, Huntington JA, Conard J, Carrell RW. Antithrombin 'DREUX' (Lys 114Glu): a variant with complete loss of heparin affinity. Thromb Haemost 2002; 88: 436-43.
33. Chang W-SW, Harper PL. Commercial antithrombin concentrate contains inactive L-forms of antithrombin. Thromb Haemost 1997; 77: 323-8.
34. Collen D, Schetz J, de Cock F, Holmer E, Verstraete M. Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration. Eur J Clin Invest 1977; 7: 27-35.